{
  "title": "M21-1, Part VIII, Subpart ii, Chapter 1, Section D - Presumptive Service Connection (SC) for Infectious Disease Under 38 CFR 3.317",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000259721/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-D-Presumptive-Service-Connection-SC-for-Infectious-Disease-Under-38-CFR-3317",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nGeneral Information on Presumptive SC for Infectious Diseases Under 38 CFR 3.317(c)\n2\nDeveloping Claims for Infectious Disease Under 38 CFR 3.317\n3\nRating Claims for Infectious Disease Under 38 CFR 3.317\n1\n.\nGeneral Information on Presumptive SC for Infectious Diseases Under 38 CFR 3.317(c)\nIntroduction\nThis topic contains general information on presumptive SC for infectious diseases under 38 CFR 3.317(c), including\nqualifying service for presumptive SC of infectious diseases under 38 CFR 3.317\npresumptive SC for infectious diseases under 38 CFR 3.317(c)\nmanifestation period for infectious diseases under 38 CFR 3.317\n, and\nconsidering long-term health effects potentially associated with infectious diseases\n.\nChange Date\nJanuary 29, 2024\nVIII.ii.1.D.1.a\n.\nQualifying Service for Presumptive SC of Infectious Diseases Under 38 CFR 3.317\nQualifying service for the purpose of presumptive service connection (SC) for infectious diseases, means the Veteran served on active duty\nin the Southwest Asia theater of operations during the Gulf War, as defined in\n38 CFR 3.317(e)\n, or\nin Afghanistan on or after September 19, 2001.\nImportant\n:  While some of the service locations overlap, qualifying service for the purposes of presumptive SC for infectious diseases is not equivalent to Persian Gulf Veteran service outlined in\n38 U.S.C. 1117\nfor presumptive SC of undiagnosed illnesses and medically unexplained chronic multi-symptom illness (MUCMIs).\nPublic Law 117-168\n, Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022, did not change qualifying service or the other regulatory requirements for infectious diseases.\nReferences\n:  For more information on\nqualifying service for presumptive SC of infectious diseases, see\n38 CFR 3.317(c)(3)(ii)\n, and\ndefinition of Persian Gulf war, see\n38 CFR 3.2(i)\n.\nVIII.ii.1.D.1.b\n.\nPresumptive SC for Infectious Diseases Under 38 CFR 3.317(c)\nEffective September 29, 2010, presumptive SC is established under\n38 CFR 3.317(c)\nfor the specified infectious diseases if\nthe Veteran had qualifying service as detailed in\nM21-1, Part VIII, Subpart ii, 1.D.1.a\n, and\nthe disease becomes manifest to a compensable degree within the time limit specified in\n38 CFR 3.317(c)(3)(i)\nand\nM21-1, Part VIII, Subpart ii, 1.A.2.c\n.\nVIII.ii.1.D.1.c\n.\nManifestation Period for Infectious Diseases Under 38 CFR 3.317\nFor each of the recognized presumptive infectious diseases,\n38 CFR 3.317(c)(3)(i)\nprescribes a specific manifestation period as detailed in the table below.\nNote\n:  The one-year time period specified in the table below means within one year from the date of separation from a qualifying period of service as specified in\n38 CFR 3.317 (c)(3)(ii)\n.\nInfectious Disease\nTime Limit for Manifestation\nBrucellosis\none year\nCampylobacter jejuni\none year\nCoxiella burnetii (Q fever)\none year\nMalaria\none year, or\nat a time when standard or accepted treatises indicate that the incubation period began during a qualifying period of service\nMycobacterium tuberculosis\nno time limit\nNontyphoid Salmonella\none year\nShigella\none year\nVisceral leishmaniasis\nno time limit\nWest Nile virus\none year\nReferences\n:  For more information on\ndeveloping infectious disease claims, see\nM21-1, Part VIII, Subpart ii, 1.D.2\n, and\nestablishing onset of a presumptive disability during a required manifestation period, see\nM21-1, Part V, Subpart ii, 2.B.1.g\n.\nVIII.ii.1.D.1.d\n.\nConsidering Long-Term Health Effects Potentially Associated With Infectious Diseases\nAs specified in\n38 CFR 3.317(d)\n, if a Veteran who is presumed SC for a disease listed in column A of the table is diagnosed with a disease in column B within the time period specified in the table (if no time period is specified, at any time), the Department of Veterans Affairs (VA) will request a medical opinion as to whether it is at least as likely as not that the condition was caused by the Veteran having had the associated disease in column A.\nNote\n:  This does not preclude a finding that other manifestations of disability or secondary conditions were caused by an infectious disease.\nColumn A – Infectious Disease\nColumn B – Associated Condition(s)\nBrucellosis\narthritis\ncardiovascular, nervous, and respiratory system infections\nchronic meningitis and mengocephalitis\ndeafness\ndemyelinating meningovascular syndromes\nepiscleritis\nfatigue, inattention, amnesia, and depression\nGuillain-Barre syndrome\nhepatic abnormalities, including granulomatous hepatitis\nmultifocal choroiditis\nmyelitis-radiculoneuritis\nnummular keratitis\npapilledema\noptic neuritis\norchioepididymitis and infections of the genitourinary system\nsensorineural hearing loss\nspondylitis\nuveitis\nCampylobacter jejuni\nGuillain-Barre syndrome if manifest within two months of the infection\nreactive arthritis if manifest within three months of the infection\nuveitis if manifest within one month of the infection\nCoxiella burnetti (Q fever)\nchronic hepatitis\nendocarditis\nosteomyelitis\npost-Q-fever chronic fatigue syndrome\nvascular infection\nMalaria\ndemyelinating polyneuropathy\nGuillain-Barre syndrome\nhematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria)\nimmune-complex glomerulonephritis\nneurologic disease, neuropsychiatric disease, or both\nophthalmologic manifestations, particularly retinal hemorrhage and scarring\nPlasmodium falciparum\nPlasmodium malariae\nPlasmodium ovale\nPlasmodium vivax\nrenal disease, especially nephrotic syndrome\nMycobacterium tuberculosis\nactive tuberculosis\nlong-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis\nNontyphoid Salmonella\nreactive arthritis if manifest within three months of the infection\nShigella\nhemolytic-uremic syndrome if manifest within one month of the infection\nreactive arthritis if manifest within three months of the infection\nVisceral leishmaniasis\ndelayed presentation of the acute clinical syndrome\npost-kala-azar dermal leishmaniasis if manifest within two years of the infection\nreactivation of visceral leishmaniasis in the context of future immunosuppression\nWest Nile virus\nvariable physical, functional, or cognitive disability\nReference\n:  For more information on requesting medical opinions in claims for infectious diseases, see\nM21-1, Part VIII, Subpart ii, 1.D.2.c\n.\n2\n.\nDeveloping Claims for Infectious Disease Under 38 CFR 3.317\nIntroduction\nThis topic contains information on developing claims of infectious disease under 38 CFR 3.317, including\nSection 5103 notice for infectious disease claims\ndeveloping claims for infectious diseases\n, and\nrequesting examinations in claims for infectious diseases\n.\nChange Date\nJanuary 29, 2024\nVIII.ii.1.D.2.a\n.\nSection 5103 Notice for Infectious Disease Claims\nIt is unnecessary to issue Section 5103 notice when a Veteran files a new claim for SC for an infectious disease on a form that provides, or otherwise indicates the claimant received, the notice, such as\nVA Form 21-526EZ, Application for Disability Compensation and Related Compensation Benefits\n.\nReferences\n:  For more information on\ncircumstances under which it is necessary to issue Section 5103 notice, see\nM21-1, Part III, Subpart i, 2.B.1.b\n, and\nM21-1, Part X, Subpart ii, 2.A.1.c\nrequesting evidence from the claimant, see\nM21-1, Part III, Subpart i, 2.D\n, and\nclarifying contentions, see\nM21-1, Part III, Subpart i, 2.D.1.c\n.\nVIII.ii.1.D.2.b\n.\nDeveloping Claims for Infectious Diseases\nIn addition to the usual evidence-gathering procedures for claims, follow the procedures below when processing a claim for SC of an infectious disease under\n38 CFR 3.317\n.\nStep\nAction\n1\nDoes the Veteran have qualifying service as defined in\n38 CFR 3.317(c)(3)(ii)\nand as detailed in\nM21-1, Part VIII, Subpart ii, 1.D.1.a\n?\nIf\nyes\n, go to next step.\nIf\nno\n, send the claim for a decision.\n2\nIs there credible lay or medical evidence of a qualifying infectious disease within the time limit, if applicable, specified in\n38 CFR 3.317(c)(3)(i)\n?\nIf\nyes\n, go to the next step.\nIf\nno\n, send the claim for a decision.\n3\nIs the Veteran claiming one of the long-term health effects listed in\n38 CFR 3.317(d)(2)\ndue to the infectious disease?\nIf\nyes\n, go to the next step.\nIf\nno\n, go to Step 5.\n4\nIs there credible lay or medical evidence of the long-term health effect, and if applicable, within the time limit specified in\n38 CFR 3.317(d)(2)\n?\nIf\nyes\n,\nrequest a medical opinion as outlined in\nM21-1, Part VIII, Subpart ii, 1.D.2.c\n, and\ngo to the next step.\nIf\nno\n, go to the next step.\n5\nRequest an examination for the infectious disease, if needed to decide the claim, following the guidance in\nM21-1, Part VIII, Subpart ii, 1.D.2.c\n.\nReference\n:  For more information on infectious diseases under\n38 CFR 3.317\nand potential long-term health effects, see\nM21-1, Part VIII, Subpart ii, 1.D.1.d\n.\nVIII.ii.1.D.2.c\n.\nRequesting Examinations in Claims for Infectious Diseases\nUse the table below when an examination and/or medical opinion is needed to decide a claim for infectious disease under\n38 CFR 3.317\n.\nIf the claim involves a(n) ...\nThen ...\ninfectious disease listed in\n38 CFR 3.317(c)\nrequest the appropriate infectious diseases DBQ to evaluate current severity.\nNote\n:  As presumptive SC applies to the infectious disease under\n38 CFR 3.317\n, a medical opinion is not required.\nlong-term health effect potentially associated with an infectious disease as noted in\n38 CFR 3.317(d)\nrequest a medical opinion as to whether it is at least as likely as not that the condition was caused by the Veteran having had the infectious disease.\nImportant\n:\nDo not request a Gulf War general medical examination for infectious disease claims.\nThe Acceptable Clinical Evidence (ACE) examination process may be used when processing these claims, when deemed appropriate.\nReference\n:  For more information on ACE examinations, see\nM21-1, Part IV, Subpart i, 2.A.4\n.\n3.  Rating Claims for Infectious Disease Under 38 CFR 3.317\nChange Date\nJanuary 29, 2024\nVIII.ii.1.D.3.a.  Proper Coding for Infectious Disease Decisions Under 38 CFR 3.317\nIn order to properly identify and track infectious disease claims for which SC is awarded or denied under\n38 CFR 3.317\n, regional offices must properly code the disabilities in the Veterans Benefits Management System - Ratings (VBMS-R) by assigning the\nGulf War Presumptive\nspecial issue, and\nspecial issue basis specific to the infectious disease.\nReference\n:  For more information on assigning a special issue in VBMS-R, see the\nVBMS-R User Guide\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177440\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section C - Rating Presumptive Service Connection (SC) Claims for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177440/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-C-Rating-Presumptive-Service-Connection-SC-Claims-for-Persian-Gulf-Veterans\"> &lt;-- Previous Section</a>  <a articleid=\"554400000177441\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 2, Section A - General Information on Claims Based on Exposure to Burn Pits and Other Toxins, Including Fine Particulate Matter (BPOT)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177441/M21-1-Part-VIII-Subpart-ii-Chapter-2-Section-A-General-Information-on-Claims-Based-on-Exposure-to-Burn-Pits-and-Other-Toxins-Including-Fine-Particulate-Matter-BPOT\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In This Section</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This section contains the following topics: </span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 0px; width: 495px; border-spacing: 0px; border-collapse: revert;\" width=\"495\"><tbody><tr><td style=\"width: 87px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic</strong></span></span></div></td><td style=\"width: 333px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic Name</strong></span></span></div></td></tr><tr><td style=\"width: 87px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"width: 333px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1\" target=\"_self\">General Information on Presumptive SC for Infectious Diseases Under 38 CFR 3.317(c)</a></span></span></div></td></tr><tr><td style=\"width: 87px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 333px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2\" target=\"_self\">Developing Claims for Infectious Disease Under 38 CFR 3.317</a></span></span></div></td></tr><tr><td style=\"width: 87px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></div></td><td style=\"width: 333px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3\" target=\"_self\">Rating Claims for Infectious Disease Under 38 CFR 3.317</a></span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><h2 class=\"ng-scope\"> <span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">1<a id=\"1\" name=\"1\">.</a>  General Information on Presumptive SC for Infectious Diseases Under 38 CFR 3.317(c)</span></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">This topic contains general information on presumptive SC for infectious diseases under 38 CFR 3.317(c), including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\">qualifying service for presumptive SC of infectious diseases under 38 CFR 3.317</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\">presumptive SC for infectious diseases under 38 CFR 3.317(c)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1c\" target=\"_self\">manifestation period for infectious diseases under 38 CFR 3.317</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1d\" target=\"_self\">considering long-term health effects potentially associated with infectious diseases</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 29, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">VIII.ii.1.D.1.a<a id=\"1a\" name=\"1a\">.</a>  Qualifying Service for Presumptive SC of Infectious Diseases Under 38 CFR 3.317 </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div class=\"BulletText1\" style=\"margin-left: 0in; text-indent: 0in\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"tab-stops: .5in\">Qualifying service for the purpose of presumptive service connection (SC) for infectious diseases, means the Veteran served on active duty </span></span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">in the Southwest Asia theater of operations during the Gulf War, as defined in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(e)</a>, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">in Afghanistan on or after September 19, 2001.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Important</i></b>:  While some of the service locations overlap, qualifying service for the purposes of presumptive SC for infectious diseases is not equivalent to Persian Gulf Veteran service outlined in <a href=\"https://www.law.cornell.edu/uscode/text/38/1117\" target=\"_blank\">38 U.S.C. 1117</a> for presumptive SC of undiagnosed illnesses and medically unexplained chronic multi-symptom illness (MUCMIs).  <i>Public Law 117-168</i>, Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022, did not change qualifying service or the other regulatory requirements for infectious diseases.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>References</i></b>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">qualifying service for presumptive SC of infectious diseases, see <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(c)(3)(ii)</a>, and</span> </span></li><li><span style=\"font-size: 14px\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">definition of Persian Gulf war, see<a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFRf5fe31f49d4f511/section-3.2\" target=\"_blank\">38 CFR 3.2(i)</a></span>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">VIII.ii.1.D.1.b<a id=\"1b\" name=\"1b\">.</a>  Presumptive SC for Infectious Diseases Under 38 CFR 3.317(c)</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Effective September 29, 2010, presumptive SC is established under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(c)</a> for the specified infectious diseases if</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the Veteran had qualifying service as detailed in <a href=\"#1a\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.1.a</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the disease becomes manifest to a compensable degree within the time limit specified in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(c)(3)(i)</a> and <a articleid=\"554400000177434\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section A - General Information on Presumptive Service Connection (SC) for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177434/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-A-General-Information-on-Presumptive-Service-Connection-SC-for-Persian-Gulf-Veterans\">M21-1, Part VIII, Subpart ii, 1.A.2.c</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">VIII.ii.1.D.1.c<a id=\"1c\" name=\"1c\">.</a>  Manifestation Period for Infectious Diseases Under 38 CFR 3.317 </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">For each of the recognized presumptive infectious diseases, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(c)(3)(i)</a> prescribes a specific manifestation period as detailed in the table below.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  The one-year time period specified in the table below means within one year from the date of separation from a qualifying period of service as specified in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317 (c)(3)(ii)</a>.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"This is an infectious disease-time limit for manifestation table.  Column 1 contains the infectious disease name and column 2 contains the time limit for manifestation.\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 319px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong>Infectious Disease</strong></span></span></div></th><th scope=\"col\" style=\"width: 319px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong>Time Limit for Manifestation</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Brucellosis</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Campylobacter jejuni</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Coxiella burnetii (Q fever)</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Malaria</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">at a time when standard or accepted treatises indicate that the incubation period began during a qualifying period of service </span></span></div></li></ul></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Mycobacterium tuberculosis</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">no time limit</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Nontyphoid Salmonella</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Shigella</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Visceral leishmaniasis</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">no time limit</span></span></div></td></tr><tr><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">West Nile virus</span></span></div></td><td style=\"width: 319px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">one year</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">developing infectious disease claims, see <a href=\"#2\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.2</a>, and</span></span></div></li><li><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">establishing onset of a presumptive disability during a required manifestation period, see <a articleid=\"554400000180482\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section B - Presumptive Service Connection (SC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180482/M21-1-Part-V-Subpart-ii-Chapter-2-Section-B-Presumptive-Service-Connection-SC\">M21-1, Part V, Subpart ii, 2.B.1.g</a>.  </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.ii.1.D.1.d<a id=\"1d\" name=\"1d\">.</a>  Considering Long-Term Health Effects Potentially Associated With Infectious Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">As specified in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(d)</a>, if a Veteran who is presumed SC for a disease listed in column A of the table is diagnosed with a disease in column B within the time period specified in the table (if no time period is specified, at any time), the Department of Veterans Affairs (VA) will request a medical opinion as to whether it is at least as likely as not that the condition was caused by the Veteran having had the associated disease in column A. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  This does not preclude a finding that other manifestations of disability or secondary conditions were caused by an infectious disease.</span></span></div><div></div><div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"This is a infectious disease-associated condition(s) table.  Column 1 or Column A is the infectious disease name and column 2 or column B contains the associated condition(s).\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 230px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Column A – Infectious Disease</strong></span></span></span></span></div></th><th scope=\"col\" style=\"width: 276px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Column B – Associated Condition(s)</strong></span></span></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Brucellosis</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">arthritis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cardiovascular, nervous, and respiratory system infections</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic meningitis and mengocephalitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">deafness</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">demyelinating meningovascular syndromes</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">episcleritis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fatigue, inattention, amnesia, and depression</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Guillain-Barre syndrome</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hepatic abnormalities, including granulomatous hepatitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">multifocal choroiditis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">myelitis-radiculoneuritis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">nummular keratitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">papilledema</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">optic neuritis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">orchioepididymitis and infections of the genitourinary system</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sensorineural hearing loss</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">spondylitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">uveitis</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Campylobacter jejuni</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Guillain-Barre syndrome if manifest within two months of the infection</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">reactive arthritis if manifest within three months of the infection</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">uveitis if manifest within one month of the infection</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Coxiella burnetti (Q fever)</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic hepatitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">endocarditis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">osteomyelitis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">post-Q-fever chronic fatigue syndrome</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">vascular infection</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Malaria</span></span></span></span></div><div></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">demyelinating polyneuropathy</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Guillain-Barre syndrome</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria)</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">immune-complex glomerulonephritis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">neurologic disease, neuropsychiatric disease, or both</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">ophthalmologic manifestations, particularly retinal hemorrhage and scarring</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Plasmodium falciparum</em></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Plasmodium malariae</em></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Plasmodium ovale</em></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Plasmodium vivax</em></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">renal disease, especially nephrotic syndrome</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Mycobacterium tuberculosis</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">active tuberculosis</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Nontyphoid Salmonella</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">reactive arthritis if manifest within three months of the infection</span></span></span></span></div></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Shigella</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hemolytic-uremic syndrome if manifest within one month of the infection</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">reactive arthritis if manifest within three months of the infection</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Visceral leishmaniasis</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">delayed presentation of the acute clinical syndrome</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">post-kala-azar dermal leishmaniasis if manifest within two years of the infection</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">reactivation of visceral leishmaniasis in the context of future immunosuppression</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 230px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">West Nile virus</span></span></span></span></div></td><td style=\"width: 276px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">variable physical, functional, or cognitive disability</span></span></span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on requesting medical opinions in claims for infectious diseases, see <a href=\"#2c\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.2.c</a>.</span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><div><hr/></div></div><h2 class=\"ng-scope\"><br/><br/><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Developing Claims for Infectious Disease Under 38 CFR 3.317</span></span></h2><div class=\"ng-scope\"> <br/> </div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">This topic contains information on developing claims of infectious disease under 38 CFR 3.317, including</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2a\" target=\"_self\">Section 5103 notice for infectious disease claims</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2b\" target=\"_self\">developing claims for infectious diseases</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2c\" target=\"_self\">requesting examinations in claims for infectious diseases</a>.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 29, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.ii.1.D.2.a<a id=\"2a\" name=\"2a\">.</a>  Section 5103 Notice for Infectious Disease Claims</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">It is unnecessary to issue Section 5103 notice when a Veteran files a new claim for SC for an infectious disease on a form that provides, or otherwise indicates the claimant received, the notice, such as <em><a href=\"http://www.vba.va.gov/pubs/forms/VBA-21-526EZ-ARE.pdf\" target=\"_blank\">VA Form 21-526EZ, Application for Disability Compensation and Related Compensation Benefits</a></em>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">circumstances under which it is necessary to issue Section 5103 notice, see</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000014101\" articlename=\"M21-1, Part III, Subpart i, Chapter 2, Section B - Duty to Notify Under 38 U.S.C. 5103\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014101/M21-1-Part-III-Subpart-i-Chapter-2-Section-B-Duty-to-Notify-Under-38-USC-5103\">M21-1, Part III, Subpart i, 2.B.1.b</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177963\" articlename=\"M21-1, Part X, Subpart ii, Chapter 2, Section A - Revision Based on Specific Types of Submissions, Including Supplemental Claims\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177963/M21-1-Part-X-Subpart-ii-Chapter-2-Section-A-Revision-Based-on-Specific-Types-of-Submissions-Including-Supplemental-Claims\">M21-1, Part X, Subpart ii, 2.A.1.c</a></span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">requesting evidence from the claimant, see <a articleid=\"554400000033257\" articlename=\"M21-1, Part III, Subpart i, Chapter 2, Section D - Evidence Requested From the Claimant\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000033257/M21-1-Part-III-Subpart-i-Chapter-2-Section-D-Evidence-Requested-From-the-Claimant\">M21-1, Part III, Subpart i, 2.D</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">clarifying contentions, see <a articleid=\"554400000033257\" articlename=\"M21-1, Part III, Subpart i, Chapter 2, Section D - Evidence Requested From the Claimant\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000033257/M21-1-Part-III-Subpart-i-Chapter-2-Section-D-Evidence-Requested-From-the-Claimant\">M21-1, Part III, Subpart i, 2.D.1.c</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">VIII.ii.1.D.2.b<a id=\"2b\" name=\"2b\">.</a>  Developing Claims for Infectious Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In addition to the usual evidence-gathering procedures for claims, follow the procedures below when processing a claim for SC of an infectious disease under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"width: 510px; border-spacing: 0px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides the action to take when processing a claim for SC of an infectious disease under 38 CFR 3.317.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 0px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">Step</span></span></div></th><th scope=\"col\" style=\"width: 438px; padding: 0px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">Action</span></span></div></th></tr></thead><tbody><tr><td style=\"width: 72px; padding: 0px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">1</span></span></div></td><td style=\"width: 438px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Does the Veteran have qualifying service as defined in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(c)(3)(ii)</a> and as detailed in <a href=\"#1a\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.1.a</a>?</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>yes</i>, go to next step. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>no</i>, send the claim for a decision.</span></span></li></ul></div></td></tr><tr><td style=\"width: 72px; padding: 0px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">2</span></span></div></td><td style=\"width: 438px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Is there credible lay or medical evidence of a qualifying infectious disease within the time limit, if applicable, specified in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(c)(3)(i)</a>?</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>yes</i>, go to the next step.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>no</i>, send the claim for a decision.</span></span></li></ul></div></td></tr><tr><td style=\"width: 72px; padding: 0px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">3</span></span></div></td><td style=\"width: 438px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Is the Veteran claiming one of the long-term health effects listed in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(d)(2)</a> due to the infectious disease?</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>yes</i>, go to the next step.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>no</i>, go to Step 5.</span></span></li></ul></div></td></tr><tr><td style=\"width: 72px; text-align: center; padding: 0px;\">4</td><td style=\"width: 438px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Is there credible lay or medical evidence of the long-term health effect, and if applicable, within the time limit specified in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(d)(2)</a>?</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>yes</i>,</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">request a medical opinion as outlined in <a href=\"#2c\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.2.c</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">go to the next step.   </span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If <i>no</i>, go to the next step.</span></span></li></ul></td></tr><tr><td style=\"width: 72px; text-align: center; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">5</span></span></td><td style=\"width: 438px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Request an examination for the infectious disease, if needed to decide the claim, following the guidance in <a href=\"#2c\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.2.c</a>.</span></span></td></tr></tbody></table></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on infectious diseases under <a href=\"http://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317</a> and potential long-term health effects, see <a href=\"#1d\" target=\"_self\">M21-1, Part VIII, Subpart ii, 1.D.1.d</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">VIII.ii.1.D.2.c<a id=\"2c\" name=\"2c\">.</a>  Requesting Examinations in Claims for Infectious Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Use the table below when an examination and/or medical opinion is needed to decide a claim for infectious disease under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317</a>.</span></span></div><div></div><div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"width: 510px; border-spacing: 0px; border-collapse: revert;\" summary=\"This is an If-Then table.  Column 1 provides the criteria and column 2 provides the actions to take when requesting an exam.\" width=\"510\"><thead><tr><th style=\"width: 198px; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the claim involves a(n) ...</span></span></div></th><th style=\"width: 312px; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Then ...</span></span></div></th></tr></thead><tbody><tr><td style=\"width: 198px; vertical-align: top; text-align: left; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"color: black\">infectious disease listed in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(c)</a></span></span></span></div></td><td style=\"width: 318px; vertical-align: top; text-align: left; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">request the appropriate infectious diseases DBQ to evaluate current severity.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i><span style=\"color: black\">Note</span></i></b><span style=\"color: black\">:  As presumptive SC applies to the infectious disease under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317</a>, a medical opinion is not required.</span></span></span></div></div></td></tr><tr><td style=\"width: 198px; vertical-align: top; text-align: left; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"color: black\">long-term health effect potentially associated with an infectious disease as noted in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317\" target=\"_blank\">38 CFR 3.317(d)</a> </span></span></span></div></td><td style=\"width: 318px; vertical-align: top; text-align: left; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"color: black\">request a medical opinion as to whether it is at least as likely as not that the condition was caused by the Veteran having had the infectious disease.</span></span></span></td></tr></tbody></table></div><div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Important</strong></em>:  </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Do not request a Gulf War general medical examination for infectious disease claims. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The Acceptable Clinical Evidence (ACE) examination process may be used when processing these claims, when deemed appropriate.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on ACE examinations, see <a articleid=\"554400000180498\" articlename=\"M21-1, Part IV, Subpart i, Chapter 2, Section A - Examination Requests Overview\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180498/M21-1-Part-IV-Subpart-i-Chapter-2-Section-A-Examination-Requests-Overview\">M21-1, Part IV, Subpart i, 2.A.4</a>.</span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">3.  Rating Claims for Infectious Disease Under 38 CFR 3.317  </span></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 29, 2024 </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.ii.1.D.3.a.  Proper Coding for Infectious Disease Decisions Under 38 CFR 3.317</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In order to properly identify and track infectious disease claims for which SC is awarded or denied under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=d672e020c675fe0b1e527d621e26aaa6&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317</a>, regional offices must properly code the disabilities in the Veterans Benefits Management System - Ratings (VBMS-R) by assigning the</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em>Gulf War Presumptive </em>special issue, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">special issue basis specific to the infectious disease.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on assigning a special issue in VBMS-R, see the <em>VBMS-R User Guide</em>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177440\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section C - Rating Presumptive Service Connection (SC) Claims for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177440/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-C-Rating-Presumptive-Service-Connection-SC-Claims-for-Persian-Gulf-Veterans\"> &lt;-- Previous Section</a>  <a articleid=\"554400000177441\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 2, Section A - General Information on Claims Based on Exposure to Burn Pits and Other Toxins, Including Fine Particulate Matter (BPOT)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177441/M21-1-Part-VIII-Subpart-ii-Chapter-2-Section-A-General-Information-on-Claims-Based-on-Exposure-to-Burn-Pits-and-Other-Toxins-Including-Fine-Particulate-Matter-BPOT\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\" style=\"text-align: left\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 11px\"><a href=\"#top\" target=\"_self\">To Top</a></span></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=9f0ce8e46464a943446b3eabce7d0edb&node=se38.1.3_1317&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=d672e020c675fe0b1e527d621e26aaa6&node=se38.1.3_1317&rgn=div8",
    "http://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317",
    "http://www.vba.va.gov/pubs/forms/VBA-21-526EZ-ARE.pdf",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.317",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFRf5fe31f49d4f511/section-3.2",
    "https://www.law.cornell.edu/uscode/text/38/1117"
  ],
  "scraped_at": "2025-06-16T22:56:55.328120",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177441/M21-1-Part-VIII-Subpart-ii-Chapter-2-Section-A-General-Information-on-Claims-Based-on-Exposure-to-Burn-Pits-and-Other-Toxins-Including-Fine-Particulate-Matter-BPOT"
}